𝔖 Bobbio Scriptorium
✦   LIBER   ✦

613 Docetaxel (DOC) and mitoxantrone (MIT) in the management of hormone refractory prostate cancer (HRPCA)

✍ Scribed by A. Heidenreich; A. Schrader; P. Olbert; C. Ohlmann; A. Hegel; R. Hofmann

Book ID
118645819
Publisher
Elsevier Science
Year
2004
Tongue
English
Weight
225 KB
Volume
3
Category
Article
ISSN
1569-9056

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Activity of second-line chemotherapy in
Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : Randomized phase 2 study of ixabepilone or mitoxantrone and prednisone
✍ Jonathan E. Rosenberg; Vivian K. Weinberg; W. Kevin Kelly; Dror Michaelson; Maha πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 147 KB πŸ‘ 1 views

## Abstract ## BACKGROUND. This randomized, noncomparative, multicenter, clinical trial evaluated ixabepilone or mitoxantrone/prednisone (MP) as second‐line chemotherapy for taxane‐refractory, hormone‐refractory, prostate cancer (HRPC). ## METHODS. Patients with HRPC that progressed during or wi